ONCT News and Press, Oncternal Therapeutics Inc. From 07/14/22

Oncternal Therapeutics ( NASDAQ: ONCT ) on Thursday said it had entered into a clinical trial collaboration with AbbVie ( ABBV ) company Pharmacyclics to support its phase 3 lymphoma study. ONCT stock gained ~9% to $1.22 after hours. As per the terms of the...

Clinical trial collaboration supports global registrational Phase 3 study ZILO-301, to treat patients with relapsed or refractory MCL with zilovertamab plus ibrutinib Agreement is supportive of the planned initiation of ZILO-301 in Q3 2022 and will also supply ibrutinib for the ...

The following slide deck was published by Oncternal Therapeutics, Inc. in conjunction with this event. For further details see: Oncternal Therapeutics (ONCT) Investor Presentation -slideshow

The following slide deck was published by Oncternal Therapeutics, Inc. in conjunction with this event. For further details see: onct

SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that preclinical data from its ROR1-targeting cell therapy programs will be highlighte...

Oncternal Therapeutics (NASDAQ:ONCT) said it will begin a phase 3 trial of ZILO-301, a combination of its experimental monocolonal antibody zilovertamab with Imbruvica (ibrutinib), for mantle cell lymphoma (MCL) in Q3. The study, which will enroll ~250 people, will evaluate the potential bene...

SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the rationale and plans for its upcoming Phase 3 ZILO-301 (zilovertamab plus ibru...

ONCT already has great data in MCL, but that data further improved as the Phase 2 study matured. I parse some of the results and compare them to previous data from current standard of care ibrutinib. Based on the entirety of its data, ONCT is initiating a Phase 3 MCL registrationa...

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the Jefferies Healthcare Conference being held J...

Oncternal Therapeutics (NASDAQ:ONCT) granted options to buy 70K common shares to its new employee Ted Shih, who joined as head, Clinical Science. The award was made on June 1 under Oncternal's 2021 Employment Inducement Incentive Award Plan, and can be exercise at $1.56 per share, w...